Galena Biopharma Launches Abstral Sublingual Tablets for Treatment of Breakthrough Cancer Pain

Galena Biopharma (NASDAQ: GALE ) today announced the official product launch of Abstral® (fentanyl) Sublingual Tablets in the United States. Abstral is a sublingual (under the tongue) fentanyl tablet indicated for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already